<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BW619C89 (4-amino-2-(4-methylpiperazin-l-yl)-5-(2,3,5-trichlorophenyl) <z:chebi fb="0" ids="16898">pyrimidine</z:chebi>) was evaluated for cerebroprotection after focal or global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>BW619C89, as the mesylate dihydrate salt, 20 mg kg-1, i.v. for 10 min immediately, or with a 1 h delay after permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in Fischer rats reduces cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (visualized with (2,3,5-triphenyltetrazolium) by 49% (p &lt; 0.05) or by 61% (p &lt; 0.001) and improves neurological deficit </plain></SENT>
<SENT sid="2" pm="."><plain>Administration of BW619C89 with a 2 h delay is ineffective </plain></SENT>
<SENT sid="3" pm="."><plain>BW619C89, given i.p </plain></SENT>
<SENT sid="4" pm="."><plain>0 and 4 h after 20 min of transient bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> in vertebral artery-occluded Wistar rats reduces <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release and neuronal cell loss in the hippocampal CA1 sector (p &lt; 0.01) and striatum (p &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>BW619C89 resembles BW1003C87 (5-(2,3,5-trichlorophenyl)-2,4-diaminopyrimidine) in inhibiting <z:chebi fb="0" ids="28051">veratrine</z:chebi>-induced <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release and protecting against ischaemic brain damage </plain></SENT>
</text></document>